141 related articles for article (PubMed ID: 12235008)
1. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim IY; Kim BC; Seong DH; Lee DK; Seo JM; Hong YJ; Kim HT; Morton RA; Kim SJ
Cancer Res; 2002 Sep; 62(18):5365-9. PubMed ID: 12235008
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Kim IY; Seong DH; Kim BC; Lee DK; Remaley AT; Leach F; Morton RA; Kim SJ
Cancer Res; 2002 Jul; 62(13):3649-53. PubMed ID: 12097269
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
4. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
5. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
Liu J; Matsuo H; Xu Q; Chen W; Wang J; Maruo T
Hum Reprod; 2007 May; 22(5):1253-9. PubMed ID: 17220163
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells.
Yeh JY; Huang WJ; Kan SF; Wang PS
J Urol; 2001 Nov; 166(5):1937-42. PubMed ID: 11586264
[TBL] [Abstract][Full Text] [Related]
7. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature.
Olivier S; Close P; Castermans E; de Leval L; Tabruyn S; Chariot A; Malaise M; Merville MP; Bours V; Franchimont N
Mol Pharmacol; 2006 May; 69(5):1615-23. PubMed ID: 16497877
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
Shazer RL; Jain A; Galkin AV; Cinman N; Nguyen KN; Natale RB; Gross M; Green L; Bender LI; Holden S; Kaplan L; Agus DB
BJU Int; 2006 Apr; 97(4):691-7. PubMed ID: 16536755
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145.
Yun JM; Kweon MH; Kwon H; Hwang JK; Mukhtar H
Carcinogenesis; 2006 Jul; 27(7):1454-64. PubMed ID: 16497706
[TBL] [Abstract][Full Text] [Related]
11. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
12. Selenium effects on prostate cell growth.
Menter DG; Sabichi AL; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1171-82. PubMed ID: 11097224
[TBL] [Abstract][Full Text] [Related]
13. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells.
Yu CH; Kan SF; Pu HF; Jea Chien E; Wang PS
Cancer Sci; 2008 Dec; 99(12):2467-76. PubMed ID: 19037992
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis of human prostate androgen-dependent and -independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) 18.
Hostanska K; Nisslein T; Freudenstein J; Reichling J; Saller R
Anticancer Res; 2005; 25(1A):139-47. PubMed ID: 15816531
[TBL] [Abstract][Full Text] [Related]
16. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
17. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
[TBL] [Abstract][Full Text] [Related]
18. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
19. Growth response of colon cancer cell lines to selective estrogen receptor modulators.
Picariello L; Fiorelli G; Martineti V; Tognarini I; Pampaloni B; Tonelli F; Brandi ML
Anticancer Res; 2003; 23(3B):2419-24. PubMed ID: 12894523
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cell growth and induction of apoptosis in human prostate cancer cell lines by 6-aminoquinolone WM13.
Minelli A; Bellezza I; Siciliano E; Liguori L; Tabarrini O; Cecchetti V; Fravolini A
Oncol Rep; 2005 Jun; 13(6):1113-20. PubMed ID: 15870930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
